Found 400 Enz. Inhib. hit(s) with all data for entry = 2493 
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting Her2 exon 20 YVMA insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line,...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Ariad Pharmaceuticals
US Patent
Ariad Pharmaceuticals
US Patent
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Ariad Pharmaceuticals
US Patent
Ariad Pharmaceuticals
US Patent
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting Her2 exon 20 YVMA insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line,...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting Her2 exon 20 YVMA insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line,...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Ariad Pharmaceuticals
US Patent
Ariad Pharmaceuticals
US Patent
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting Her2 exon 20 YVMA insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line,...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting Her2 exon 20 YVMA insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line,...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Ariad Pharmaceuticals
US Patent
Ariad Pharmaceuticals
US Patent
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Ariad Pharmaceuticals
US Patent
Ariad Pharmaceuticals
US Patent
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Ariad Pharmaceuticals
US Patent
Ariad Pharmaceuticals
US Patent
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Ariad Pharmaceuticals
US Patent
Ariad Pharmaceuticals
US Patent
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Ariad Pharmaceuticals
US Patent
Ariad Pharmaceuticals
US Patent
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Ariad Pharmaceuticals
US Patent
Ariad Pharmaceuticals
US Patent
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 20 insertion mutations can be assessed using Ba/F3 cells, a murine pro-B cell line, whic...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Ariad Pharmaceuticals
US Patent
Ariad Pharmaceuticals
US Patent
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Ariad Pharmaceuticals
US Patent
Ariad Pharmaceuticals
US Patent
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR L858R and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine pro-B cell l...More data for this Ligand-Target Pair
Affinity DataIC50: <100nMAssay Description:A compound's ability in selectively inhibiting EGFR exon 19 deletion and T790M concurrent mutations can be assessed using Ba/F3 cells, a murine p...More data for this Ligand-Target Pair
